Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385335 | 0.89 | KCNH2 (0.58) | METKCNH2BMPR1BBMPR1AACVRL1 | |
| SCHEMBL2387017 | 0.88 | MET (0.70) | METKCNH2 | |
| SCHEMBL2386761 | 0.86 | MET (0.55) | METKCNH2BMPR1BBMPR1AACVRL1 | |
| SCHEMBL2387371 | 0.84 | MET (0.57) | METKCNH2BMPR1BBMPR1AACVRL1 | |
| SCHEMBL2386111 | 0.84 | MET (0.57) | METKCNH2BMPR1BBMPR1AACVRL1 | |
| SCHEMBL2386099 | 0.82 | MAP4K4 (0.58) | MET | |
| SCHEMBL2384703 | 0.82 | FYN (0.60) | METKCNH2 | |
| SCHEMBL2385727 | 0.78 | NPC1 (0.57) | MET | |
| SCHEMBL2387550 | 0.76 | ATR (0.48) | BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL2387793 | 0.76 | FYN (0.47) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | MET 2362/4885KCNH2 833/4885BMPR1B 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.